Two repair pathways. One prescription.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
Recovery can stall for more than one reason.
There is a particular kind of injury that is functional enough to stop being acute, but never good enough to become irrelevant. You can train on it. You can work around it. You can also tell exactly where the ceiling still is.
BPC-157 and TB-500 approach that plateau from different parts of the repair process.
Research shows BPC-157 promotes new blood-vessel growth through VEGFR2, a signaling pathway involved in angiogenesis.1 TB-500 is a compounded peptide related to thymosin beta-4, a naturally occurring protein involved in the internal scaffolding that lets cells change shape and move. In preclinical wound models, thymosin beta-4 attracts endothelial cells toward damaged tissue and accelerates wound closure,2 while research on a short actin-binding segment shows key wound-repair activity.3
One side of the story is access. The other is movement. Repair requires both the environment around damaged tissue and the cells doing the work inside it.
The combination is built around division of labor. BPC-157 has been studied in angiogenesis and tendon-cell repair models, while thymosin beta-4 research examines endothelial-cell movement and wound closure. Their different roles are the reason to consider them together.
- Hsieh MJ, et al. J Mol Med. 2017.
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical… FASEB J. 1997.
- Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003.PubMed
For the recovery that got stuck at almost.
Eighty Percent Became Permanent
The tendon is usable again, but the limit has not moved in months. You have spent enough time at the same plateau to stop calling it patience.
Training Around It Became the Program
You are back in the gym or back on the road, but every session still has an asterisk. The old injury has become part of how you plan everything else.
It Came Back Twice
The same spot has failed you more than once. At that point, the quality of the rebuild deserves as much attention as the original incident.
Compounded BPC-157 / TB-500 is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
- Competing in a tested sport, unless you have confirmed the position with your governing body
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Wolverine Stack, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Two distinct peptide components selected around complementary parts of the repair process
- A licensed provider reviews the injury, medical history, medications, and full combination before prescribing
- Dose and duration are set for you, with follow-up built into the plan
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Recovery & Repair.
BPC-157
The peptide everyone asks about, inside real medicine.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
BPC-157 Oral
A capsule that meets the digestive tract directly.
Compounded oral BPC-157 delivered directly into the digestive tract, with a clinician deciding whether capsule or injection fits the case.
Wolverine 2.0
Add the inflammation layer.
A compounded three-peptide prescription that adds a distinct inflammation and comfort layer to the recovery conversation.
Do not use if you have
- Active or suspected malignancy
Serious risks
- BPC-157 acts on blood vessel formation
- Thymosin beta-4 has been shown in laboratory work to push colon cancer cells toward the mobile, invasive state that precedes spread
Commonly reported
- Mostly local: soreness, redness or swelling where you inject
Two things drive the screening here. Neither finding says this preparation causes cancer. Both are why a provider screens carefully for any history of it. Both compounds are prohibited at all times by the World Anti-Doping Agency, in and out of competition, so if you are a tested athlete, say so at intake. Human safety data is limited, which is the reason this sits with a clinician rather than in a shopping cart.
- Huang HC, et al. Thymosin beta4 triggers an epithelial-mesenchymal transition in… Oncogene. 2007.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
In July 2026 an FDA advisory committee voted to recommend both of the compounds in this preparation, BPC-157 and TB-500, for pharmacy compounding. That recommendation is advisory and the agency has not yet acted on it. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
A recovery plateau is not a diagnosis and it does not come with a universal clock. Your provider looks at the tissue, the injury, how long progress has been flat, and what happens after treatment starts, then adjusts from there.
A peptide combination is only as serious as the medical system around it. Here, a licensed provider decides whether BPC-157 and TB-500 belong together in your care, and a licensed US pharmacy compounds the prescription specifically for you. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. The difference is accountability before the medication ever reaches you, and someone medically responsible for what happens after it does.
Any time, before your renewal date. No phone calls required.
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.